646 related articles for article (PubMed ID: 24415859)
1. Inflammatory pathways of importance for management of inflammatory bowel disease.
Pedersen J; Coskun M; Soendergaard C; Salem M; Nielsen OH
World J Gastroenterol; 2014 Jan; 20(1):64-77. PubMed ID: 24415859
[TBL] [Abstract][Full Text] [Related]
2. Target-Based Small Molecule Drug Discovery Towards Novel Therapeutics for Inflammatory Bowel Diseases.
Li Y; Chen J; Bolinger AA; Chen H; Liu Z; Cong Y; Brasier AR; Pinchuk IV; Tian B; Zhou J
Inflamm Bowel Dis; 2021 Nov; 27(Suppl 2):S38-S62. PubMed ID: 34791293
[TBL] [Abstract][Full Text] [Related]
3. Development of drugs to target interactions between leukocytes and endothelial cells and treatment algorithms for inflammatory bowel diseases.
Danese S; Panés J
Gastroenterology; 2014 Nov; 147(5):981-9. PubMed ID: 25220794
[TBL] [Abstract][Full Text] [Related]
4. Potential role of nutraceutical compounds in inflammatory bowel disease.
Larussa T; Imeneo M; Luzza F
World J Gastroenterol; 2017 Apr; 23(14):2483-2492. PubMed ID: 28465632
[TBL] [Abstract][Full Text] [Related]
5. Molecular mechanism of action of anti-tumor necrosis factor antibodies in inflammatory bowel diseases.
Billmeier U; Dieterich W; Neurath MF; Atreya R
World J Gastroenterol; 2016 Nov; 22(42):9300-9313. PubMed ID: 27895418
[TBL] [Abstract][Full Text] [Related]
6. The Innate and Adaptive Immune System as Targets for Biologic Therapies in Inflammatory Bowel Disease.
Holleran G; Lopetuso L; Petito V; Graziani C; Ianiro G; McNamara D; Gasbarrini A; Scaldaferri F
Int J Mol Sci; 2017 Sep; 18(10):. PubMed ID: 28934123
[TBL] [Abstract][Full Text] [Related]
7. Immunotherapy in inflammatory bowel disease: Novel and emerging treatments.
Catalan-Serra I; Brenna Ø
Hum Vaccin Immunother; 2018; 14(11):2597-2611. PubMed ID: 29624476
[TBL] [Abstract][Full Text] [Related]
8. Novel therapeutic targets for inflammatory bowel disease.
Argollo M; Fiorino G; Hindryckx P; Peyrin-Biroulet L; Danese S
J Autoimmun; 2017 Dec; 85():103-116. PubMed ID: 28711286
[TBL] [Abstract][Full Text] [Related]
9. Development, validation and implementation of an in vitro model for the study of metabolic and immune function in normal and inflamed human colonic epithelium.
Pedersen G
Dan Med J; 2015 Jan; 62(1):B4973. PubMed ID: 25557335
[TBL] [Abstract][Full Text] [Related]
10. Oncostatin M drives intestinal inflammation and predicts response to tumor necrosis factor-neutralizing therapy in patients with inflammatory bowel disease.
West NR; Hegazy AN; Owens BMJ; Bullers SJ; Linggi B; Buonocore S; Coccia M; Görtz D; This S; Stockenhuber K; Pott J; Friedrich M; Ryzhakov G; Baribaud F; Brodmerkel C; Cieluch C; Rahman N; Müller-Newen G; Owens RJ; Kühl AA; Maloy KJ; Plevy SE; ; Keshav S; Travis SPL; Powrie F
Nat Med; 2017 May; 23(5):579-589. PubMed ID: 28368383
[TBL] [Abstract][Full Text] [Related]
11. Biologic therapy for inflammatory bowel disease.
Ardizzone S; Bianchi Porro G
Drugs; 2005; 65(16):2253-86. PubMed ID: 16266194
[TBL] [Abstract][Full Text] [Related]
12. New strategies for treatment of inflammatory bowel disease.
Nielsen OH
Front Med (Lausanne); 2014; 1():3. PubMed ID: 25685754
[TBL] [Abstract][Full Text] [Related]
13. When combination therapy isn't working: emerging therapies for the management of inflammatory bowel disease.
Krishnareddy S; Swaminath A
World J Gastroenterol; 2014 Feb; 20(5):1139-46. PubMed ID: 24574790
[TBL] [Abstract][Full Text] [Related]
14. Biologic therapies against inflammatory bowel disease: a dysregulated immune system and the cross talk with gastrointestinal mucosa hold the key.
Dharmani P; Chadee K
Curr Mol Pharmacol; 2008 Nov; 1(3):195-212. PubMed ID: 20021434
[TBL] [Abstract][Full Text] [Related]
15. Application of Drug Repurposing Approach for Therapeutic Intervention of Inflammatory Bowel Disease.
Bhat MA; Usman I; Dhaneshwar S
Curr Rev Clin Exp Pharmacol; 2024; 19(3):234-249. PubMed ID: 37859409
[TBL] [Abstract][Full Text] [Related]
16. Emerging therapeutic targets and strategies in Crohn's disease.
Furfaro F; Fiorino G; Allocca M; Gilardi D; Danese S
Expert Rev Gastroenterol Hepatol; 2016 Jun; 10(6):735-44. PubMed ID: 26766496
[TBL] [Abstract][Full Text] [Related]
17. A State-of-the-Art Review of New and Emerging Therapies for the Treatment of IBD.
Chudy-Onwugaje KO; Christian KE; Farraye FA; Cross RK
Inflamm Bowel Dis; 2019 Apr; 25(5):820-830. PubMed ID: 30445504
[TBL] [Abstract][Full Text] [Related]
18. An update on biosimilar drugs for inflammatory bowel disease.
Schreiber S
Expert Rev Gastroenterol Hepatol; 2015; 9 Suppl 1():1-3. PubMed ID: 26395529
[TBL] [Abstract][Full Text] [Related]
19. Inflammatory Bowel Disease: Pathophysiology and Current Therapeutic Approaches.
Abraham BP; Ahmed T; Ali T
Handb Exp Pharmacol; 2017; 239():115-146. PubMed ID: 28233184
[TBL] [Abstract][Full Text] [Related]
20. Current Status of Medical Therapy for Inflammatory Bowel Disease: The Wealth of Medications.
Nadpara N; Reichenbach ZW; Ehrlich AC; Friedenberg F
Dig Dis Sci; 2020 Oct; 65(10):2769-2779. PubMed ID: 32661765
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
